EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy

Carlo Giannangelo iD, Matthew P Challis, Ghizal Siddiqui, Rebecca Edgar, Tess R Malcolm, Chaille T Webb, Nyssa Drinkwater, Natalie Vinh, Christopher Macraild, Natalie Counihan iD, Sandra Duffy, Sergio Wittlin und 6 weitere

eLife · 2024

DOI: 10.7554/elife.92990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Carlo Giannangelo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Plasmodium vivax, Protozoan Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Medicines for Malaria Venture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New antimalarial drug candidates that act via novel mechanisms are urgently needed to combat malaria drug resistance. Here, we describe the multi-omic chemical validation of Plasmodium M1 alanyl metalloaminopeptidase as an attractive drug target using the selective inhibitor, MIPS2673. MIPS2673 demonstrated potent inhibition of recombinant Plasmodium falciparum ( Pf A-M1) and Plasmodium vivax ( Pv A-M1) M1 metalloaminopeptidases, with selectivity over other Plasmodium and human aminopeptidases, and displayed excellent in vitro antimalarial activity with no significant host cytotoxicity. Orthogonal label-free chemoproteomic methods based on thermal stability and limited proteolysis of whole parasite lysates revealed that MIPS2673 solely targets Pf A-M1 in parasites, with limited proteolysis also enabling estimation of the binding site on Pf A-M1 to within ~5 Å of that determined by X-ray crystallography. Finally, functional investigation by untargeted metabolomics demonstrated that MIPS2673 inhibits the key role of Pf A-M1 in haemoglobin digestion. Combined, our unbiased multi-omic target deconvolution methods confirmed the on-target activity of MIPS2673, and validated selective inhibition of M1 alanyl metalloaminopeptidase as a promising antimalarial strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumPlasmodium vivaxProtozoan ProteinsProteomicsHumansAminopeptidases

Stichwörter der Autor:innen

P. falciparumaminopeptidasebiochemistrychemical biologychemoproteomicsdrug targetinfectious diseasemalariamass spectrometrymetabolomicsmicrobiology

Substanzen

AntimalarialsProtozoan ProteinsAminopeptidases

Autor:innen und Institutionen

  • Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • School of Medicine, Deakin University, Geelong, Australia.
  • The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
  • Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Australia.
  • Centre to Impact AMR, Monash University, Clayton, Australia.
  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.

ORCID-Profile: Carlo Giannangelo, Natalie Counihan, Shane M Devine, Sheena McGowan, Darren J Creek

Förderung

  • National Health and Medical Research Council
  • Medicines for Malaria Venture

Zitieren

APA

Giannangelo, C., Challis, M. P., Siddiqui, G., Edgar, R., Malcolm, T. R., Webb, C. T., Drinkwater, N., Vinh, N., Macraild, C., Counihan, N., Duffy, S., Wittlin, S., Devine, S. M., Avery, V. M., De Koning-Ward, T., Scammells, P., McGowan, S., & Creek, D. J. (2024). Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy. eLife. https://doi.org/10.7554/elife.92990

Vancouver

Giannangelo C, Challis MP, Siddiqui G, Edgar R, Malcolm TR, Webb CT, et al. Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy. eLife. 2024. doi:10.7554/elife.92990

BibTeX
@article{Giannangelo2024,
  author = {Giannangelo, Carlo and Challis, Matthew P and Siddiqui, Ghizal and Edgar, Rebecca and Malcolm, Tess R and Webb, Chaille T and Drinkwater, Nyssa and Vinh, Natalie and Macraild, Christopher and Counihan, Natalie and Duffy, Sandra and Wittlin, Sergio and Devine, Shane M and Avery, Vicky M and De Koning-Ward, Tania and Scammells, Peter and McGowan, Sheena and Creek, Darren J},
  title = {Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.92990}
}
Kostenlos starten →